Neumora Therapeutics, Inc. Common Stock
NMRANeumora Therapeutics, Inc. is a biotechnology company focused on developing targeted therapies for central nervous system (CNS) disorders. It leverages innovative neuroscience science and digital health tools to create precision medicines aimed at improving outcomes for patients with neurological and psychiatric conditions.
Company News
Neumora Therapeutics announced that its Phase 3 KOASTAL-2 and -3 studies of navacaprant failed to achieve primary endpoints for major depressive disorder treatment, leading the company to discontinue the program. The company is refocusing on three other clinical programs (NMRA-511, NMRA-898, and NMRA-215) and implementing a 35% workforce reductio...
The Schall Law Firm is investigating Neumora Therapeutics, Inc. (NASDAQ: NMRA) on behalf of investors for potential securities law violations. The investigation focuses on whether the company issued false or misleading statements or failed to disclose material information to investors.
Neumora Therapeutics announced it will host a conference call on March 30, 2026, to report Q4 and full year 2025 financial results and provide a business update. The clinical-stage biopharmaceutical company highlighted its 2026 pipeline strategy with multiple clinical data readouts expected, including consolidated topline readouts for KOASTAL-2 a...
Neumora Therapeutics, a clinical-stage biopharmaceutical company, announced it will participate in a fireside chat at the Guggenheim Emerging Outlook: Biotech Summit 2026 on February 11, 2026. The company highlighted its 2026 pipeline strategy with multiple clinical data readouts expected, including KOASTAL-2 and -3 trials anticipated for Q2 2026...
Three clinical-stage biotech companies are leveraging AI to advance drug discovery and treatment in areas like aging, neuroscience, and oncology, with promising platforms that use machine learning to analyze complex biological data.
